Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters
NCT06074237 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112
Last updated 2026-01-22
Summary
Unfortunately, only 40% of US pediatric residency programs reported in a survey that vaccine safety and counseling training is provided to residents. The success of a residency curriculum focused on communication strategies with patients hesitant to receive the influenza vaccine has been demonstrated, finding a decreased rate of vaccination refusal in the post curricular period. In a recent 2020 study, it demonstrated the positive impact of an online vaccine curriculum on resident vaccine knowledge and self-reported confidence in counseling vaccine hesitant patients.
Providers have the potential to impact a substantial pediatric patient population. The outpatient clinics where the residents included in this study care for patients had 9942 pediatric visits in 2021. Each visit is an opportunity to talk with families about vaccines, address concerns and to administer vaccines when needed. The hypothesize is that interactive educational interventions using the online training modules combined with the standardized patient encounters will increase resident vaccine knowledge and confidence, and enhance communication and counseling skills, thereby improving vaccination rates of Human Papilloma Virus (HPV), Influenza, Measles/Mumps/Rubella (MMR) and Coronavirus (COVID-19) in the Beaumont residency clinics.
Conditions
- Vaccine Refusal
- Vaccine-Preventable Diseases
- Physician-Patient Relations
Interventions
- OTHER
-
Immersive resident education
Using the AIMS framework (Announce, Inquire, Mirror, Secure), residents will complete online modules designed to improve vaccine education, promote vaccine confidence and improve vaccine counseling in general. There will also be modules dispelling myths and controversies specific to HPV, MMR, Covid and influenza vaccines that often limit or prevent vaccination uptake.
- OTHER
-
Standardized patient (SP) encounter
After completion of the Immersive Resident Education modules, residents will participate in a telemedicine standardized patient encounter. They will interview a vaccine-hesitant "patient" and this encounter will be video recorded. At the end of the encounter, the SP will provide the resident with patient-centered feedback on their communication skills. The SP will also complete a communication checklist regarding each resident encounter and the research team will review the recorded encounters for accuracy of medical content conveyed during each encounter.
Sponsors & Collaborators
- collaborator INDUSTRY
-
Corewell Health East
lead OTHER
Principal Investigators
-
Andrea C Hernandez Troya, MD · Corewell Health East
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-25
- Primary Completion
- 2025-06-27
- Completion
- 2025-06-27
Countries
- United States
Study Locations
More Related Trials
-
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
NCT00471081 ·Status: COMPLETED ·Phase: PHASE2
-
Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season
NCT06603090 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study With QIVc in Pediatric Subjects
NCT03932682 ·Status: COMPLETED ·Phase: PHASE3
-
Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): Its' Correlation Factors and an Educational Intervention Programme
NCT04930185 ·Status: UNKNOWN ·Phase: NA
-
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
NCT01214837 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
NCT07003984 ·Status: RECRUITING ·Phase: PHASE3
-
Tailoring of Vaccine-Focused Messages: Moral Foundations
NCT02851459 ·Status: COMPLETED ·Phase: NA
-
Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin
NCT01119534 ·Status: UNKNOWN ·Phase: PHASE3
-
Impact of PACV Administration on Vaccine Hesitancy
NCT04450940 ·Status: COMPLETED ·Phase: NA
-
COVIDVaxStories: Randomized Trial to Reduce COVID-19 Vaccine Hesitancy in Populations of Color
NCT06297876 ·Status: COMPLETED ·Phase: NA
-
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age
NCT03165617 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age
NCT02919293 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
NCT03691610 ·Status: COMPLETED ·Phase: PHASE3
-
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
NCT01823536 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
NCT00310817 ·Status: COMPLETED ·Phase: PHASE2
-
Improving the School Vaccination Experience: What CARDs Are You Going to Play?
NCT03966300 ·Status: TERMINATED ·Phase: NA
-
Dose Comparison Study of Menactra® in US Children
NCT00700635 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
NCT00806195 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
NCT06337071 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico
NCT03630705 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
NCT00384397 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children
NCT02153112 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
NCT02534935 ·Status: COMPLETED ·Phase: PHASE2
-
Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults
NCT04232943 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age
NCT04358731 ·Status: COMPLETED ·Phase: PHASE2/PHASE3